ClinicalTrials.gg

Program

Poliovirus Vaccine, Inactivated

Also written as “sIPV”, “IPV” and “Poliorix™”.

Its studies are mostly in Poliomyelitis · Gastroenteritis · Streptococcal Infections · Tetanus, led by 7 companies.

Furthest: phase 4, since Oct 19, 200716 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline50 open or runningphase 3since Oct 19, 2007Oct 19, 2007none ahead
Sinovac Biotech41 open or runningphase 4since Jan 29, 2024May 4, 2018none ahead
Beijing Minhai Biotechnology20 open or runningphase 3since Dec 12, 2024Dec 12, 2024none ahead
Johnson & Johnson20 open or runningphase 2since Jun 12, 2018Jan 24, 2017none ahead
E-MO Biology10 open or runningphase 4since Nov 16, 2020Nov 16, 2020none ahead
Sinopharm10 open or runningphase 4since Aug 8, 2019Aug 8, 2019none ahead
Takeda10 open or runningphase 2since Mar 24, 2017Mar 24, 2017none ahead

Also a collaborator on its studies: Beijing Institute of Biological Products.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Oct 19, 2007.

  1. Nov 25, 2009Phase 3 study in PoliomyelitisGlaxoSmithKline · NCT01021293 · 1,101 enrolled · China
  2. Oct 6, 2011Phase 3 study in TetanusGlaxoSmithKline · NCT01449812 · 831 enrolled · China
  3. Jan 24, 2017Johnson & Johnson’s first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT03032588 · 32 enrolled · Belgium
  4. Mar 24, 2017Takeda’s first study: phase 2 study in PoliomyelitisNew to TakedaTakeda · NCT03092791 · 340 enrolled · Panama
  5. May 4, 2018Sinovac Biotech’s first study: phase 3 study in PoliomyelitisNew to Sinovac BiotechSinovac Biotech · NCT03526978 · 1,200 enrolled · China
  6. Jun 12, 2018Phase 2 study in HealthyJohnson & Johnson · NCT03566940 · 302 enrolled · Philippines
  7. Aug 8, 2019Sinopharm’s first study: phase 4 study in VaccinationNew to SinopharmSinopharm · NCT04051736 · 360 enrolled · China
  8. Nov 16, 2020E-MO Biology’s first study: phase 4 study in SARS-CoV-2New to E-MO BiologyE-MO Biology · NCT04639375 · 300 enrolled · United States
  9. Jan 29, 2024Phase 4 study in PoliomyelitisSinovac Biotech · NCT06346834 · 200 enrolled · China
  10. Mar 19, 2024Phase 3 study in GastroenteritisGlaxoSmithKline · NCT06331156 · 400 enrolled · China
  11. May 29, 2024Phase 4 study in PoliomyelitisSinovac Biotech · NCT06442449 · 889 enrolled · China
  12. Dec 12, 2024Beijing Minhai Biotechnology’s first study: phase 3 study in PoliomyelitisNew to Beijing Minhai BiotechnologyBeijing Minhai Biotechnology · NCT06752174 · 300 enrolled · China
  13. Apr 22, 2025Phase 4 study in PoliomyelitisSinovac Biotech · NCT07354269 · 180 planned · China
  14. Dec 9, 2025Phase 3 study in PoliomyelitisBeijing Minhai Biotechnology · NCT07297186 · 1,200 enrolled · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“A vaccine consisting of inactivated poliovirus (IPV) types 1,2 and 3, with active immunizing activity against poliomyelitis”NCIt, by rule

Studies

All 16 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07297186Poliomyelitis · China3CompletedBeijing Minhai BiotechnologyApr 10, 20231,200
NCT07354269Poliomyelitis · China4RecruitingSinovac BiotechApr 11, 2026180
NCT06752174Poliomyelitis · China3CompletedBeijing Minhai BiotechnologyApr 12, 2024300
NCT06442449Poliomyelitis · China4CompletedSinovac BiotechSep 10, 2025889
NCT06331156Gastroenteritis · China3CompletedGlaxoSmithKlineOct 22, 2024400
NCT06346834Poliomyelitis · China4CompletedSinovac BiotechSep 6, 2024200
NCT04639375SARS-CoV-2 · United States4UNKNOWNE-MO BiologyJun 12, 2021300
NCT04051736Vaccination · China4CompletedSinopharmDec 28, 2018360
NCT03566940Healthy · Philippines2CompletedJohnson & JohnsonAug 7, 2019302
NCT03526978Poliomyelitis · China3CompletedSinovac BiotechOct 18, 20171,200
NCT03092791Poliomyelitis · Panama2TerminatedTakedaApr 3, 2018340
NCT03032588Healthy · Belgium1CompletedJohnson & JohnsonMay 18, 201832
NCT01449812Tetanus · China3CompletedGlaxoSmithKlineJan 16, 2012831
NCT01021293Poliomyelitis · China3CompletedGlaxoSmithKlineJul 5, 20101,101
NCT00937404Poliomyelitis · China1CompletedGlaxoSmithKlineNov 13, 200925
NCT00547248Streptococcal Infections · Philippines, Poland3CompletedGlaxoSmithKlineMay 10, 2008756

How it is read

Names in the registry

  • “sIPV”, 6 entries
  • “IPV”, 3 entries
  • “Poliorix™”, 2 entries
  • “Poliorix”, 2 entries
  • “sIPV+bOPV”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.